Newsroom archive

RELAX PIIIb Data
31 . 01 .2025
Press release
IMCAS 2025: New Galderma phase IIIb data reinforce rapid onset and long-lasting aesthetic improvement with RelabotulinumtoxinA (Relfydess™)
  • Global release
Medication driven wight loss Masterclass
30 . 01 .2025
Press release
Galderma demonstrates Injectable Aesthetics leadership in medication-driven weight loss with new research and first international consensus-based guidelines
  • Global release
IMCAS 2025 curtain raiser
23 . 01 .2025
Press release
IMCAS 2025: Galderma’s broad presence and new data on recently launched products Restylane® SHAYPE™ and Relfydess® reaffirm its category leadership
  • Global release
IMCAS 2025
23 . 01 .2025
News story
IMCAS 2025: Galderma’s Scientific Presentations
addressing facial volume loss as a result of medication-driven weight loss
14 . 01 .2025
Press release
Galderma premieres positive interim results demonstrating the efficacy of its Injectable Aesthetics portfolio in addressing facial volume loss as a result of medication-driven weight loss
  • Global release
NEXT_GAIN_Thumbnail
19 . 12 .2024
News story
Beyond trends: equipping the aesthetics community for what’s NEXT
US FDA approval nemluvio AD
14 . 12 .2024
Press release
Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis
  • Key Release
positive CHMP opinion in atopic dermatitis and prurigo nodularis
13 . 12 .2024
Press release
CHMP recommends approval of Galderma’s nemolizumab for moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union
  • Global release
JAMA 2024
28 . 11 .2024
Press release
Galderma’s phase III OLYMPIA 1 data published in JAMA Dermatology demonstrate that nemolizumab improves core signs and symptoms of prurigo nodularis
  • Global release
Sculptra 25
04 . 11 .2024
Press release
Celebrating 25 years of Sculptra®: new data and recent approval in China cements Galderma’s leadership in regenerative biostimulation
  • Global release